TEVA•benzinga•May 7, 2025 at 11:05 AM

Teva Pharmaceutical Indus Raises FY2025 Adj EPS Guidance From $2.35-$2.65 To $2.45-$2.65 vs $2.55 Est; Narrows FY2025 Sales Guidance From $16.80B-$17.40B To $16.80B-$17.20B vs $17.24B Est

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 7, 2025 by benzinga